BioSpace News Archive

AsclepiX Therapeutics, Inc. announced that it has closed a $35 million Series A financing led by Perceptive Xontogeny Venture Fund with participation from the Perceptive Life Sciences Fund, both funds managed by Perceptive Advisors, and existing investors Rapha Capital Management and Barer & Son Capital.

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia.

Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer’s Disease program on July 8, 2020 at 8:15 AM ET

Antimicrobial resistance is a leading global health challenge i that requires urgent action to ensure a safer world for everyone, everywhere Effective surveillance and timely data feedback are critical for infection prevention and control programs, and informing appropriate use of anti-infectives New partnership in Ghana, Kenya, Malawi and Uganda will provide governments and public health community with critical decision-making inform

HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a phase 2 clinical trial of HST5040, an oral small molecule drug for the treatment of patients

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the wor

Mayne Pharma Group Limited is pleased to announce the New Drug Application for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration.

The global opioid induced constipation treatment market is highly consolidated with the presence of few companies.

The global spinal muscular atrophy market witnesses substantial competition with the presence of a considerable number of market participants of varying sizes, says Transparency Market Research in a new market study.

The vendor landscape of the kidney cancer drugs market is largely consolidated and competitive in nature.